Testing clot-busting drug during stroke treatment for medium vessel blockages
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether giving a clot-dissolving medication directly into the brain's blood vessels during a standard procedure (mechanical thrombectomy) can improve outcomes for people with a stroke caused by a blockage in a medium-sized artery. It may be an option for patients who arrive at the hospital within 24 hours of symptom onset and have enough salvageable brain tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had a stroke caused by a blockage in a medium-sized brain artery (like the M2, M3, M4, A1–A3, P1–P3 segments).
- Your stroke symptoms are at least moderately severe (NIHSS score of 6 or more).
- Treatment can start within 6 hours of when you were last seen well, or within 6–24 hours if imaging shows brain tissue that can still be saved.
- You do not have bleeding in the brain, a major disability before the stroke, or any serious bleeding risk.
- You are not pregnant, do not have severe kidney problems, and are not allergic to contrast dye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new clot-busting medicine called tenecteplase, given directly into the blood vessel in the brain, to treat strokes caused by a blockage in a medium-sized artery. The goal is to see if it can help restore blood flow and reduce disability, especially for patients who can be treated within 24 hours of stroke onset.
This trial tests whether giving a clot-busting drug called tenecteplase directly into the blocked blood vessel in the brain can help people with a medium-sized vessel occlusion stroke. The drug may help restore blood flow and reduce disability, and it is given within 24 hours of symptom onset.
This trial tests a clot-dissolving drug called tenecteplase given 4.5 to 24 hours after a stroke caused by a blockage in a medium-sized brain artery. It aims to see if waiting longer than usual still helps reduce disability.
This trial tests giving a clot-dissolving medicine (rhPro-UK) through a vein before a procedure to remove a large blood clot in the brain. It is for people who had a stroke 4.5 to 24 hours ago and are already scheduled for clot removal. The goal is to see if the medicine helps improve blood flow and outcomes.
This trial tests if removing a large blood clot from the brain up to 3 days after a stroke improves recovery compared to standard medical care alone. It is for patients who have a severe stroke and are otherwise healthy enough for the procedure.
This trial tests if giving a clot-busting drug (tenecteplase) directly into the brain artery after a successful clot-removal procedure can improve outcomes for people with a major stroke. It is for patients who had a large vessel blockage and received endovascular thrombectomy within 24 hours of symptoms starting.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.